Janssen Withdraws Application in European Union Seeking Approval of IMBRUVICA® (ibrutinib) for the Treatment of Patients with Untreated Mantle Cell Lymphoma
- EMEA Innovative Medicine
- Janssen Withdraws Application in European Union Seeking Approval of IMBRUVICA® (ibrutinib) for the Treatment of Patients with Untreated Mantle Cell Lymphoma
Janssen Withdraws Application in European Union Seeking Approval of IMBRUVICA® (ibrutinib) for the Treatment of Patients with Untreated Mantle Cell Lymphoma
- X (Twitter)
Copy link